Treats type 2 diabetes mellitus
Type 2 diabetes mellitus, with or without drug therapy with insulin or metformin (Glucophage)
Adverse Drug Reactions
Increased serum lipid levels
Increased risk for bladder cancer
Upper respiratory tract infection
Monitor for edema, weight gain, or indications of heart failure.
Obtain serum alanine aminotransferase (ALT) levels: Baseline and every 3 to 6 months thereafter.
Stop drug therapy for indications of liver injury.
Monitor serum lipid levels.
Watch for increases in triglycerides
Watch for increases in both high-density (favorable) and low-density (unfavorable) lipoproteins.
Give orally once per day with or without food.
Follow instructions provided in access program.
Report swelling, weight gain, or shortness of breath immediately.
Report jaundice, dark urine, abdominal pain, vomiting, or fatigue
Expect periodic cholesterol testing.
Report chest pain or discomfort, diaphoresis, or atypical fatigue.
Report swelling, rapid weight gain, dyspnea
Cardiovascular disease, including hypertension
Severe heart failure
Active hepatic disease
Type 1 diabetes
Mild heart failure, risk for heart failure
Pioglitazone – may increase risk of bladder cancer after 1 year of use
Caution should be used in clients with a history of bladder cancer.
Insulin increases the risk of heart failure and edema.
Gemfibrozil (Lopid) and ketoconazole increase hypoglycemic effects.
Reduced effectiveness of contraceptives.
Glucosamine can have a negative impact on blood glucose control
Chromium as well as coenzyme Q10 can increase hypoglycemic effects.